论文部分内容阅读
本刊讯(《中国医药导报》记者张浩臣)浙江中医药大学6月底在京宣布,其具有自主知识产权的抗癌中药康莱特注射液已经美国FDA认可通过,进入三期临床,在美癌症患者中扩大使用。这标志着我国中药国际化迈出了至为关键的一步。据浙江中医药大学副校长李俊伟介绍,康莱特注射液是中国工程院院士、浙江中医药大学研究员李大鹏领衔的科研团队,从中药薏苡仁中提取分离出抗癌
The Journal (“China Medical Herald” correspondent Zhang Haochen) Zhejiang University of Traditional Chinese Medicine announced in Beijing at the end of June, with its own intellectual property anti-cancer medicine Kanglaite injection has been approved by the United States FDA, entered Phase III clinical, in the United States cancer patients In the expansion of use. This indicates that the internationalization of Chinese medicine has taken a crucial step. According to Li Junwei, vice president of Zhejiang University of Traditional Chinese Medicine introduced Kanglaite injection is Chinese Academy of Engineering, Zhejiang University of Chinese Medicine researcher led by Li Dapeng research team, from Chinese medicine Yiyiren isolated anti-cancer